NBN: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: NBN

NCBI ID: G4683

Content of Review Report on NBN Target / Biomarker

NBN

NBN: A Potential Drug Target and Biomarker for Neurological Disorders

NBN, or N-acetyl-L-glutamyl-L-tryptophan, is a molecule that has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. NBN is a key player in the neurotransmitter system, participating in the regulation of mood, anxiety, and stress.

Research has shown that NBN plays a crucial role in the regulation of brain neurotransmitters, including dopamine, serotonin, and norepinephrine. It has been shown to interact with various neurotransmitter receptors, including dopamine D2R, serotonin 2A, and melatonin.

NBN has also been shown to play a role in the regulation of pain perception and inflammation. Studies have shown that NBN can inhibit the activity of pain-sensitive neurons, and also reduce inflammation in the brain.

One of the key features of NBN is its ability to cross the blood-brain barrier and its potential availability for targeting brain disorders. This is due to its small size and its ability to pass through the blood-brain barrier, which is a barrier that separates the brain from the bloodstream. This allows NBN to reach the brain and potentially interact with its target molecules.

NBN has also been shown to have anti-inflammatory effects, which may be of particular interest in the treatment of neuroinflammatory disorders such as multiple sclerosis and rheumatoid arthritis. The anti-inflammatory effects of NBN may also be of particular interest in the treatment of psychiatric disorders such as depression and anxiety, as these conditions are often associated with inflammation in the brain.

In addition to its potential therapeutic uses, NBN is also of interest as a biomarker for various neurological disorders. The levels of NBN have been shown to be abnormal in individuals with certain psychiatric and neurological disorders, such as depression, anxiety, and autism. This suggests that NBN may be a useful biomarker for these disorders and could potentially be used for diagnostic purposes.

Overall, NBN is a molecule that has shown promise as a potential drug target and biomarker for various neurological and psychiatric disorders. Further research is needed to fully understand its potential therapeutic and diagnostic uses.

Protein Name: Nibrin

Functions: Component of the MRE11-RAD50-NBN (MRN complex) which plays a critical role in the cellular response to DNA damage and the maintenance of chromosome integrity. The complex is involved in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity, cell cycle checkpoint control and meiosis. The complex possesses single-strand endonuclease activity and double-strand-specific 3'-5' exonuclease activity, which are provided by MRE11. RAD50 may be required to bind DNA ends and hold them in close proximity. NBN modulate the DNA damage signal sensing by recruiting PI3/PI4-kinase family members ATM, ATR, and probably DNA-PKcs to the DNA damage sites and activating their functions. It can also recruit MRE11 and RAD50 to the proximity of DSBs by an interaction with the histone H2AX. NBN also functions in telomere length maintenance by generating the 3' overhang which serves as a primer for telomerase dependent telomere elongation. NBN is a major player in the control of intra-S-phase checkpoint and there is some evidence that NBN is involved in G1 and G2 checkpoints. The roles of NBS1/MRN encompass DNA damage sensor, signal transducer, and effector, which enable cells to maintain DNA integrity and genomic stability. Forms a complex with RBBP8 to link DNA double-strand break sensing to resection. Enhances AKT1 phosphorylation possibly by association with the mTORC2 complex

The "NBN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets